NCT07746882Not yet recruitingPhase 3
Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
To screen ischemic stroke patients likely to benefit from anticoagulation and compare the effectiveness and safety of anticoagulation versus antiplatelet therapy in preventing recurrent ischemic stroke within 3 months.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 680 (estimated)
- First submitted
- 31 Jul 2026
- Start date
- 15 Aug 2026
- Primary completion date
- 31 Aug 2028
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Stroke
- NCT number
- NCT07746882
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 680
- From 15 Aug 2026 to the primary completion date, 31 Aug 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Indication for mandatory anticoagulation/antiplatelet therapy
- Recent brain or spinal injury/surgery
Other illness
- Malignancy
- Active bleeding (intracranial, subarachnoid, gastrointestinal, etc.)
- History of intracranial hemorrhage
- Current or recent gastrointestinal ulcer
- Severe renal impairment (CrCl \<30 ml/min)
- Liver disease with bleeding risk (Child-Pugh B or C)
Other
- Stenosis ≥50% in the responsible vessel or high-risk plaque
- Identified cardioembolic source
- PFO with planned closure
- Known or suspected vascular malformations or aneurysms
- Pregnancy or lactation
- Other contraindications to anticoagulation
Who the study is looking for
- Age ≥18 years
- Ischemic stroke patients with undetermined etiology, within 14 days of onset, with completed etiological assessment
- At least one of the following:
- Cortical or multi-territorial infarct
- Recurrent stroke or stroke on antiplatelet therapy
- Left atrial diameter \>40 mm
- Left ventricular dysfunction (EF 30-40% or regional wall motion abnormality)
- Atrial premature beats \>1500/24h
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.